{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:11:05Z","timestamp":1778710265305,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C0874"],"award-info":[{"award-number":["HI22C0874"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1C1C2007816"],"award-info":[{"award-number":["NRF-2021R1C1C2007816"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A2C2006362"],"award-info":[{"award-number":["NRF-2020R1A2C2006362"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["M-2022-C0460-00037"],"award-info":[{"award-number":["M-2022-C0460-00037"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF- 2017R1D1A1B03033660"],"award-info":[{"award-number":["NRF- 2017R1D1A1B03033660"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences","doi-asserted-by":"publisher","award":["2019IP0705"],"award-info":[{"award-number":["2019IP0705"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences","doi-asserted-by":"publisher","award":["2022IL0002"],"award-info":[{"award-number":["2022IL0002"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences","doi-asserted-by":"publisher","award":["2021IP0031"],"award-info":[{"award-number":["2021IP0031"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences","doi-asserted-by":"publisher","award":["2021IL0007"],"award-info":[{"award-number":["2021IL0007"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bbrc.2023.06.061","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:55:30Z","timestamp":1687139730000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"673","author":[{"given":"Jin","family":"Roh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Kyung","family":"Pak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0778-3134","authenticated-orcid":false,"given":"Seongfeel","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sewon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Eon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwal-Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Seong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ho","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-3548","authenticated-orcid":false,"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Sik","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.06.061_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Gascoyne","year":"2017"},{"issue":"5","key":"10.1016\/j.bbrc.2023.06.061_bib2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.bbrc.2023.06.061_bib3","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bbrc.2023.06.061_bib4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bbrc.2023.06.061_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2023.06.061_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbrc.2023.06.061_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.bbrc.2023.06.061_bib8","first-page":"1893","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL","volume":"126","author":"Offner","year":"2015","journal-title":"J.\u00a0Am. Soc. Hematol."},{"issue":"13","key":"10.1016\/j.bbrc.2023.06.061_bib9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol."},{"issue":"15","key":"10.1016\/j.bbrc.2023.06.061_bib10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bbrc.2023.06.061_bib11","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbrc.2023.06.061_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"25","key":"10.1016\/j.bbrc.2023.06.061_bib13","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bbrc.2023.06.061_bib14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase ii pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbrc.2023.06.061_bib15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase i first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbrc.2023.06.061_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A\u00a0phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbrc.2023.06.061_bib17","first-page":"1","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bbrc.2023.06.061_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051002","article-title":"Apoptotic blocks in primary non-hodgkin b cell lymphomas identified by bh3 profiling","volume":"13","author":"Rys","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2023.06.061_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","article-title":"BCL-2 family : regulators of cell death","volume":"1","author":"Chao","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bbrc.2023.06.061_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10495-014-1051-7","article-title":"The Bcl-2 family: structures, interactions and targets for drug discovery","volume":"20","author":"Kvansakul","year":"2015","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.bbrc.2023.06.061_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"issue":"JAN","key":"10.1016\/j.bbrc.2023.06.061_bib22","first-page":"1","article-title":"Targeting the Bcl-2 family in B cell lymphoma","volume":"9","author":"Adams","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2023.06.061_bib23","first-page":"1","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bbrc.2023.06.061_bib24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbrc.2023.06.061_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1515\/bmc-2016-0015","article-title":"Bcl-2 family proteins: master regulators of cell survival","volume":"7","author":"Hatok","year":"2016","journal-title":"Biomol. Concepts"},{"issue":"13","key":"10.1016\/j.bbrc.2023.06.061_bib26","first-page":"1019","article-title":"Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis","volume":"135","author":"Nguyen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.06.061_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biochi.2021.04.008","article-title":"BAP31: physiological functions and roles in disease","volume":"186","author":"Quistgaard","year":"2021","journal-title":"Biochimie"},{"key":"10.1016\/j.bbrc.2023.06.061_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ebiom.2019.09.034","article-title":"Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles","volume":"48","author":"Dubois","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bbrc.2023.06.061_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.06.061_bib30","first-page":"103","article-title":"MultiClust: an R-package for identifying biologically relevant clusters in cancer transcriptome profiles","volume":"15","author":"Lawlor","year":"2016","journal-title":"Cancer Inf."},{"issue":"11","key":"10.1016\/j.bbrc.2023.06.061_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"issue":"23","key":"10.1016\/j.bbrc.2023.06.061_bib32","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1158\/1078-0432.CCR-07-1224","article-title":"NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model","volume":"13","author":"Diallo","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbrc.2023.06.061_bib33","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.bbrc.2023.06.061_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jviscsurg.2013.10.001","article-title":"Endpoints in cancer clinical trials","volume":"151","author":"Fiteni","year":"2014","journal-title":"J.\u00a0Vis. Surg."},{"issue":"2\u20133","key":"10.1016\/j.bbrc.2023.06.061_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbamcr.2003.08.009","article-title":"The role of Bcl-2 family members in tumorigenesis","volume":"1644","author":"Kirkin","year":"2004","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.bbrc.2023.06.061_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 antiapoptotic family proteins and chemoresistance in cancer","volume":"137","author":"Maji","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.06.061_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221129710","article-title":"Gene expression profiling of FFPE samples: a titration test","volume":"21","author":"Manjunath","year":"2022","journal-title":"Technol. Cancer Res. Treat."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23008161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23008161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:36:15Z","timestamp":1778708175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23008161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"alternative-id":["S0006291X23008161"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.06.061","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.06.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}